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Background: Multidrug resistance, a major impediment to successful cancer chemotherapy, is 
the result of overexpression of ATP-binding cassette (ABC) transporters extruding   internalized 
drugs. Silencing of ABC transporter gene expression with small interfering RNA (siRNA) 
could be an attractive approach to overcome multidrug resistance of cancer, although delivery 
of siRNA remains a major hurdle to fully exploit the potential of siRNA-based therapeutics. 
Recently, we have developed pH-sensitive carbonate apatite nanoparticles to efficiently carry 
and transport siRNA across the cell membrane, enabling knockdown of the cyclin B1 gene and 
consequential induction of apoptosis in synergy with anti-cancer drugs.
Methods and results: We report that carbonate apatite-mediated delivery of the siRNAs 
t  argeting ABCG2 and ABCB1 gene transcripts in human breast cancer cells which   constitutively 
express both of the transporter genes dose-dependently enhanced chemosensitivity to doxo-
rubicin, paclitaxel and cisplatin, the traditionally used chemotherapeutic agents.   Moreover, 
codelivery of two specific siRNAs targeting ABCB1 and ABCG2 transcripts resulted in a 
more robust increase of chemosensitivity in the cancer cells, indicating the reversal of ABC 
transporter-mediated multidrug resistance.
Conclusion: The delivery concept of multiple siRNAs against ABC transporter genes is 
highly promising for preclinical and clinical investigation in reversing the multidrug resistance 
phenotype of breast cancer.
Keywords: carbonate apatite, siRNA, gene expression, transfection, breast cancer, ABC 
  transporter, multidrug resistance, chemosensitivity
Introduction
Cancer is the leading cause of deaths worldwide with breast cancer being second 
in the list of cancer related deaths.1 Among all of the available treatment options, 
  chemotherapy is the treatment of choice for advanced stage breast cancer that is 
refractory to hormonal therapy.2,3 Although traditional breast cancer chemotherapy 
regimens include combinations of cyclophosphamide, methotrexate, and 5-flurouracil,4 
anthracycline- and taxane-based chemotherapy is being commonly used nowadays for 
the treatment of breast malignancy due to its better performance in patient’s overall 
survival rate.5–7 Though breast cancer is considered to be highly chemosensitive with 
response rates as high as 80%,8 the majority of initially chemoresponsive tumours 
develop resistance to once effective chemotherapeutic agents.9 Therefore, a switch to 
other chemotherapy regimens is ineffective because of the tumour’s cross-resistance 
to multiple structurally and functionally unrelated chemotherapy drugs.10
ABC transporter represents the key component of energy-dependent efflux transport 
system contributing to the development of multidrug-resistant phenotype in cancer.11 
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ABCB1 transporter or P-glycoprotein, the first cytotoxic drug 
efflux pump to be identified,12 functions by actively extruding 
drugs including anthracyclines, taxanes, and vinca alkaloids 
out of cancer cells, thus reducing intracellular drug concen-
tration below the threshold level required for cell killing.10,11 
The poor chemotherapy response in breast cancer is gener-
ally correlated to the extent of ABCB1 gene expression.13–16 
A second type of ABC transporter discovered in a multidrug 
resistant breast cancer cell line is ABCG2,17 though there are 
no conclusive data currently available to correlate its expres-
sion with chemotherapy efficacy in breast cancer.18 However, 
judging from the ability of ABCG2 transporter in extruding 
doxorubicin, a very commonly used anthracycline drug,19 it 
might be reasonable to correlate ABCG2 expression with 
development of clinical multidrug resistance in cancer.
Although low molecular weight pharmacologically active 
compounds have been developed to circumvent multidrug-
resistant phenotypes by either directly or indirectly modulat-
ing the ABC transporter efflux activity,20 the first generation 
  modulators failed in clinical trials because of their inherent 
toxicities21 while the second generation molecules were 
associated with undesirable pharmacokinetic interactions.22,23 
Thus, no drug has been clinically approved for the reversal of 
cancer multidrug resistance.24 A new promising approach to 
enhance chemosensitivity without undesirable side effects, 
other than the structure-based drug design, is to prevent the 
biosynthesis of ABC transporters by selectively inhibiting 
the expression of ABC transporters through gene silencing 
technologies.25
In the last decade, ribozymes26–28 and antisense oligo-
nucleotides29–31 were introduced to modulate cancer multi-
drug resistance through inhibition of ABC transporter gene 
expression. Very recently, small interfering RNAs (siRNAs), 
a double-stranded RNA of between 21–28 nucleotides that 
selectively degrade mRNA and thus block production of a 
particular protein,32 have been applied in vitro for reversal 
of ABC transporter-mediated drug efflux by targeting both 
ABCB1 and ABCG2 transporters. A pioneering study using 
exogenous siRNA demonstrated suppression of ABCB1 
expression in conjunction with reversal of doxorubicin 
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Figure 1 Effect of carbonate apatite-mediated delivery of ABCg2-targeted siRNA (ABCg2_v1) on MCF-7 cell viability in presence of traditionally used chemotherapeutic 
agents. Anti-ABC siRNA-carbonate apatite complexes were generated by mixing exogenously added 3 mM calcium chloride in 1 mL bicarbonate-buffered DMEM (pH 7.4), 
followed by addition of anti-ABCg2 siRNA (1 or 10 nM) and incubation at 37°C for 30 minutes. Supplementation of 10% FBS was followed by addition of 100 nM of 
doxorubicin (A) or paclitaxel (B) or cisplatin (C).
Note: Transfection of MCF-7 cells was performed with the siRNA/nanoparticle complexes in presence of the free drugs for a consecutive period of 48 hours and viability 
of the cells was determined using MTT assay.
Abbreviations: NP, nanoparticles; siRNA, small interfering RNA; DOX, doxorubicin; PAC, paclitaxel; CISP, cisplatin.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2474
Li et alInternational Journal of Nanomedicine 2012:7
Table 1   Role  of  ABCg2  knockdown  in  enhancing  cytotoxic 
effects of anti-cancer drugs at 100 nM 
siRNA % enhancement of chemosensitivity
ABCG2 Doxorubicin Paclitaxel  Cisplatin 
100 nM 100 nM 100 nM
1 nM 28% 18% 2%
10 nM 36% 38% 17%
Abbreviation: siRNA, small interfering RNA.
and paclitaxel resistance in human breast cancer cells.33 
Reversal of multidrug-resistant ABCG2 phenotype was also 
  investigated with a siRNA-mediated knockdown study in 
several human cancer cells.34
Currently, we have established pH-sensitive carbonate 
apatite as a potential tool to efficiently deliver siRNA across 
the cell membrane and silence cyclin B1 gene transcript, 
thus inducing apoptosis of cervical cancer cells in synergy 
with anti-cancer drugs.35,36 Here, we reveal that carbonate 
apatite-mediated delivery of the siRNA targeting either 
ABCG2 or ABCB1 gene transcript in MCF-7, a human 
breast cancer cell line constitutively expressing ABCG2 and 
ABCB1 transporters, led to an increased chemosensitivity 
to doxorubicin, paclitaxel, and cisplatin, depending on the 
doses of the individual drug. Moreover, co-delivery of two 
specific siRNAs targeting ABCB1 and ABCG2 transcripts 
caused a dramatic enhancement of chemosensitivity activity 
in MCF-7 cells, indicating the reversal of ABC transporter-
mediated multidrug resistance.
Methods and materials
Materials
Dulbecco’s modified Eagle medium (DMEM) was purchased 
from BioWhittaker (Walkersville, MD). DMEM powder, fetal 
bovine serum (FBS) and trypsin-ethylenediamine   tetraacetate 
(trypsin-EDTA) were obtained from Gibco BRL (Carlsbad, 
CA). Calcium chloride dihydrate (CaCl22H2O), sodium 
bicarbonate, diammineplatinum(ll) dichloride, dimethyl 
sulphoxide (DMSO), doxorubicin hydrochloride, paclitaxel, 
and thiazolyl blue tetrazolium bromide (MTT) were from 
Sigma-Aldrich (St Louis, MO).
siRNA design and sequence
The siRNA sequence targeting ABCG2 (GenBank   accession 
no NM_004827) and ABCB1 (GenBank accession no 
NM_000927) purchased from QIAGEN (Valencia, CA) 
correspond to coding regions of these genes. One target 
sequence (5′-CTGGTCTAATTTATTAATCTA-3′) was 
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Figure 2 Effect of carbonate apatite-mediated delivery of ABCg2-targeted siRNA (ABCg2_v1) on MCF-7 cell viability in presence of low dose of traditionally used 
chemotherapeutic agents. Anti-ABC siRNA-carbonate apatite complexes were generated by mixing exogenously added 3 mM calcium chloride in 1 mL bicarbonate-buffered 
DMEM (pH 7.4), followed by addition of anti-ABCg2 siRNA (1 nM) and incubation at 37°C for 30 minutes. Supplementation of 10% FBS was followed by addition of 10 pM, 
100 pM or 1 nM of doxorubicin (A) or paclitaxel (B) or 100 pM, 1 nM, 10 nM cisplatin (C).
Note: Transfection of MCF-7 cells was performed with the siRNA/nanoparticle complexes in presence of the free drugs for a consecutive period of 48 hours and viability 
of the cells was determined using MTT assay.
Abbreviations: NP, nanoparticles; siRNA, small interfering RNA; DOX, doxorubicin; PAC, paclitaxel; CISP, cisplatin.
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selected for ABCG2 (ABCG2_v1) and one (5′-GAC-
AGAAAGCTTAGTACCAAA-3′) for ABCB1 (ABCB1_v4). 
The 21-nucleotide siRNAs having a 3′-dTdT extension were 
chosen based on recommendations made by others.37,38 
siRNA was supplied in lyophilised form and upon   delivery, 
the siRNA (1 nmol) was reconstituted with RNase-free 
water provided by manufacturer to obtain a stock solution 
of 20 µM.
Cell culture and seeding
Human breast cancer cell line MCF-7 was grown in 25 cm2 
culture flask in DMEM, supplemented with 10% heat-
  inactivated FBS in a humidified atmosphere containing 
5% CO2 at 37°C. Once the monolayer cells had reached 
80%–90% confluency, the medium was removed and the 
cells were washed with phosphate-buffered saline (PBS). 
Trypsin-EDTA was added to detach the cells from the flask 
and the suspended cells were collected in a fresh medium and 
transferred to new 25 cm2 flasks. The cells were then sub-
cultured at densities of 1.0–5.0 × 105 cells/10 mL every 3 to 
4 days. Exponentially growing MCF-7 cells (log phase) were 
trypsinised and fresh medium was added to wash remaining 
cells from the bottom of the culture flask. Cell suspension 
was centrifuged at 10,000 rpm for 5 minutes and supernatant 
was discarded. Fresh medium was then added to resuspend 
the pellet. The cells were counted using hemocytometer 
and appropriate dilutions were made using culture medium 
to produce a cell suspension with a concentration of 5.0 × 
104 cells/mL. One mL of the prepared cell suspension was 
subsequently added into each of the wells in 24-well plate 
and allowed to attach overnight at 37°C and 5% CO2 before 
siRNA transfection.
Table 2 Role of ABCg2 knockdown in enhancing cytotoxic effects of anti-cancer drugs at 10 pM to 1 nM
siRNA % enhancement of chemosensitivity
ABCG2 Doxorubicin Paclitaxel Cisplatin
10 pM 100 pM 1 nM 10 pM 100 pM 1 nM 10 pM 100 pM 1 nM
1 nM 13% 20% 14% 17% 16% 17% 5% 16% 13%
Abbreviation: siRNA, small interfering RNA.
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Figure 3 Effect of carbonate apatite-mediated delivery of ABCB1-targeted siRNA (ABCB1_v4) on MCF-7 cell viability in presence of traditionally used chemotherapeutic 
agents. Anti-ABC siRNA-carbonate apatite complexes were generated by mixing exogenously added 3 mM calcium chloride in 1 mL bicarbonate-buffered DMEM (pH 7.4), 
followed by addition of anti-ABCB1 siRNA (1 or 10 nM) and incubation at 37°C for 30 minutes. Supplementation of 10% FBS was followed by addition of 100 nM of 
doxorubicin (A) or paclitaxel (B) or cisplatin (C).
Note: Transfection of MCF-7 cells was performed with the siRNA/nanoparticle complexes in presence of the free drugs for a consecutive period of 48 hours and viability 
of the cells was determined using MTT assay.
Abbreviations: NP, nanoparticles; siRNA, small interfering RNA; DOX, doxorubicin; PAC, paclitaxel; CISP, cisplatin.
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generation of carbonate apatite 
nanoparticles containing siRNA  
and transfection of breast cancer cells
On the day of siRNA transfection, 100 mL of DMEM was 
prepared using 1.35 g of DMEM powder and 0.37 g of 
sodium bicarbonate. pH of the prepared DMEM solution was 
adjusted to 7.4 using 0.1 M hydrochloric acid. DMEM was 
then filtered using 0.2 a µm syringe filter in a laminar flow 
hood, followed by transferring 1 mL of the filtered medium 
into 1.5 mL microcentrifuge tubes. 3 µL of 1 M calcium 
chloride was then added into the microcentrifuge tubes, fol-
lowed by addition of 1 or 10 nM siRNA35,36 and incubation 
at 37°C for 30 minutes. After the incubation, 10% FBS was 
added into each microcentrifuge tube. Ten nM to 100 µM of 
a drug (doxorubicin, paclitaxel, or cisplatin) prepared from 
serial dilution using 1 mM stock solution was then added into 
the respective microcentrifuge tubes. Culture medium from 
the wells seeded one day before was aspirated and replaced 
with 1 mL of the prepared medium containing siRNA-loaded 
carbonate apatite nanoparticles and free drugs. Plates were 
then incubated at 37°C and 5% CO2 for 2 consecutive days.
Cell viability assessment with 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay
Following two days of siRNA transfection, the fraction of 
viable MCF-7 cells was determined using MTT assay as 
previously described.39 Briefly, 50 µL of MTT (5 mg/mL in 
PBS) was added aseptically into each of the wells in siRNA 
transfected plates, followed by incubation at 37°C and 5% 
CO2 for 4 hours. After the incubation period, medium con-
taining MTT was aspirated and the purple formazan crystals 
at the bottom of each well were dissolved by mixing with 
300 µL of DMSO solution. Absorbance of the resulting 
formazan solution was then determined spectrophoto-
metrically at wavelength 595 nm using a microplate reader 
(Dynex Technologies Inc., Chantilly, VA) with reference to 
630 nm. Each experiment was performed in triplicate and 
the data were plotted as mean ± standard deviation (SD) of 
three independent experiments.
Results and Discussion
Chemosensitivity enhancement in breast 
cancer cells with intracellularly delivered 
ABCG2 transcript-targeting siRNA
Since ABC transporter gene expression is essential in caus-
ing multidrug-resistant phenotype in breast cancer cells, 
knockdown of this gene might enhance sensitivity of the 
cancer cells towards chemotherapeutic agents, and possibly 
reverse cancer multidrug resistance. Therefore, MCF-7, 
the widely used human breast model cell line intrinsically 
expressing ABCG2 (alternatively called BRCP or breast 
cancer resistance protein),17 was transfected with the target 
siRNA/carbonate apatite complexes in presence or absence 
of traditionally used chemotherapeutic agents (doxorubicin, 
paclitaxel, or cisplatin) for a consecutive period of 48 hours 
prior to cell viability assessment by MTT assay. As shown in 
Figure 1A, while the viability of the cancer cells was reduced 
to 36% due to the potent cytoxicity of 100 nM doxorubicin, 
the concerted effect of siRNA delivery and drug exposure 
resulted in 26% and 24% reduction in cell viability for 1 nM 
and 10 nM of siRNA initally used for complex formation, 
respectively. Thus, the combination of siRNA and doxorubi-
cin killed a much higher number of cells than the drug and the 
siRNA alone, suggesting that silencing of the ABCG2 gene 
might have inhibited to a significant extent the efflux of 
doxorubicin across the membrane, and raised intracellular 
concentration of the drug for effective killing of the cancer 
cells (Table 1). ABCG2 gene knockdown similarly acceler-
ated chemosensitivity of paclitaxel (100 nM) particularly at 
the higher dose of siRNA (10 nM), while demonstrating an 
insignificant response with cisplatin (Figure 1B, Table 1). 
The apparent enhancement of chemosensitivity to cisplatin, 
as shown in Table 1, was virtually due to the silencing effect 
Table 4 Role of ABCB1 knockdown in enhancing cytotoxic effects of anti-cancer drugs at 10 pM to 1 nM (doxorubicin and paclitaxel) 
and 100 pM to 10 nM (cisplatin)
siRNA % enhancement of chemosensitivity
ABCB1 Doxorubicin Paclitaxel Cisplatin
10 pM 100 pM 1 nM 10 pM 100 pM 1 nM 100 pM 1 nM 10 nM
1 nM 30% 18% 18% 27% 23% 26% 4% 10% 14%
Abbreviation: siRNA, small interfering RNA.
Table 3   Role  of  ABCB1  knockdown  in  enhancing  cytotoxic 
effects of anti-cancer drugs at 100 nM
siRNA % Enhancement of chemosensitivity
ABCB1 Doxorubicin 
100 nM
Paclitaxel 
100 nM
Cisplatin 
100 nM
1 nM 7% 14% 7%
10 nM 21% 33% 21%
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Figure 4 Effect of carbonate apatite-mediated delivery of ABCB1-targeted siRNA (ABCB1_v4) on MCF-7 cell viability in presence of low dose of traditionally used 
chemotherapeutic agents. Anti-ABC siRNA-carbonate apatite complexes were generated by mixing exogenously added 3 mM calcium chloride in 1 mL bicarbonate-buffered 
DMEM (pH 7.4), followed by addition of anti-ABCB1 siRNA (1 nM) and incubation at 37°C for 30 minutes. Supplementation of 10% FBS was followed by addition of 10 pM, 
100 pM or 1 nM of doxorubicin (A) or paclitaxel (B) or 100 pM, 1 nM, 10 nM cisplatin (C).
Note: Transfection of MCF-7 cells was performed with the siRNA/nanoparticle complexes in presence of the free drugs for a consecutive period of 48 hours and viability 
of the cells was determined using MTT assay.
Abbreviations: NP, nanoparticles; siRNA, small interfering RNA; DOX, doxorubicin; PAC, paclitaxel; CISP, cisplatin.
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Figure 5 Combination effect of two siRNAs targeting ABCg2 and ABCB1 (ABCg2_v1 and ABCB1_v4 respectively) co-delivered with carbonate apatite nanoparticles on 
MCF-7 cell viability in presence of traditionally used chemotherapeutic agents. Anti-ABC siRNAs-carbonate apatite complexes were generated by mixing exogenously added 
3 mM calcium chloride in 1 mL bicarbonate-buffered DMEM (pH 7.4), followed by addition of anti-ABCg2 (1 nM) and anti-ABCB1 siRNA (1 nM) and incubation at 37°C for 
30 minutes. Supplementation of 10% FBS was followed by addition of 1 nM drug (doxorubicin, paclitaxel or cisplatin).
Note: Transfection of MCF-7 cells was performed with the siRNA/nanoparticle complexes in presence of the free drugs for a consecutive period of 48 hours and viability 
of the cells was determined using MTT assay.
Abbreviations: NP, nanoparticles; siRNA, small interfering RNA; DOX, doxorubicin; PAC, paclitaxel; CISP, cisplatin.
of siRNA (Figure 1C) alone. Indeed, the decrease in viability 
of the cells treated with siRNA/nanoparticle complexes in 
comparison with those untreated or treated with nanopar-
ticles alone indicates the role of ABC expression in delaying 
apoptosis of cancer cells.40–42
Based on the notion that anti-cancer drugs could 
dose-dependently influence the expression profile or 
susbtrate specificity of ABC transporters, a range of relatively 
lower concentrations of the drugs was investigated in the 
knockdown study of ABC transporters using 1 nM of target 
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siRNAs. As shown in Figure 2 and Table 2, with drug doses 
ranging from 10 pM to 1 nM for doxorubicin as well as 
paclitaxel and 100 pM to 10 nM for cisplatin, silencing of 
ABCG2 gene expression resulted in significant enhancement 
of chemosensitivity towards doxorubicin and paclitaxel in all 
of the drug concentrations used, whereas a weak response to 
100 pM of cisplatin was observed probably due to the poor 
cytotoxic effect of cisplatin at the particular concentration. 
The finding thus suggests that the chemosensitivity of MCF-7 
breast cancer cells due to the knockdown of ABCG2 gene 
is virtually similar among the three drugs in respect to the 
maximum enhancement and dependent on the dose of the 
invidual drug.
Chemosensitivity enhancement in breast 
cancer cells with intracellularly delivered 
ABCB1 transcript-targeting siRNA
The enhancement of chemosensitivity to the popular anti-cancer 
drugs by virtue of silencing ABCG2 gene expression trig-
gered us to carry out a similar study in the same breast cancer 
cells using the siRNA targeting the gene of ABCB1, the most 
extensively studied ABC transporter involved in development of 
multi-drug resistance in various cancer cells including MCF-7.13 
As shown in Figure 3, in synergy with 100 nM of paclitaxel, 
anti-ABCB1 siRNA at both 1 and 10 nM led to killing of much 
more cancer cells than the target siRNA (1 and 10 nM) or the 
drug (100 nM) alone, resulting in 14% and 33% enhancement 
of chemosensitivity respectively. On the contrary, the apparent 
enhancement of c  hemosensitivity (to the same extent) towards 
both 100 nM of doxorubicin and cisplatin following knock-
down of ABCB1 transporter (Table 3) was solely due to the 
effect of gene silencing killing more cells than the individual 
drugs or the target siRNA alone (Figure 3). However, when the 
doses of the individual drugs were reduced to 10 pM to 1 nM 
for doxorubicin and paclitaxel, siRNA-mediated cleavage of 
ABCB1 gene transcript surprisingly increased chemosensitivity 
towards each of the two drugs (Table 4) with demonstration of 
significantly higher level of cytotoxicity than siRNA or drugs 
alone (Figure 4), suggesting the broader substrate-specificity 
of ABCB1 transporter at lower concentrations of the individual 
cancer drugs. On ther other hand, the apparent increase in 
chemosensitivity for 100 pM to 10 nM of cisplatin was statisti-
cally insignificant, which is consistent with the fact that cisplatin 
is not a substrate for ABCB1.
Regardless of the type of siRNA (ABCG2 or ABCB1) 
used in this study, the enhancement of chemosensitivity after 
single siRNA treatment was only modest. This observation 
was similar to that made by other groups, where no complete 
reversal of cancer multidrug resistance was noted even at 
siRNA concentration as high as 200 nM.33,43 Such incomplete 
reversal of cancer multidrug resistance may be attributed to 
the inherent nature of the target protein under study. Due to its 
long half-life (from 16 hours44 to 72 hours45) and high cellular 
abundance, ABC transporter protein remains a challenging 
target for siRNA silencing.46
Chemosensitivity enhancement in breast 
cancer cells with co-delivery of two 
siRNAs targeting ABCG2 and ABCB1 
gene transcripts
Delivery of single siRNA targeting either ABCG2 or ABCB1 
transporter with carbonate apatite nanoparticles demonstrated 
a modest 15% to 30% enhancement in c  hemosensitivity in 
MCF-7 cells (Tables 1–4). To explore whether the combined 
delivery of two specific siRNAs simultaneously targeting the 
two different transporters could further improve the chemo-
sensitivity towards the anti-cancer drugs, MCF-7 cells were 
transfected with the siRNAs (at 1 nM each) targeting the 
gene transcripts of ABCG2 and ABCB1 in presence of 1 nM 
of the individual drugs. As shown in Figure 5, nanoparticle-
facilitated intracellular delivery of single siRNA targeting a 
particular transporter killed fewer cells than co-delivery of 
the two target siRNAs, suggesting that both of the transport-
ers, which are intrinsically expressed in MCF-7 cells,13,17 
are important for survival of the cells.40–42 On the other 
hand, simultaneous delivery of the two target siRNAs into 
MCF-7 cells in presence of cisplatin, paclitaxel, or doxoru-
bicin, was found to dramatically enhance cytotoxicity with 
enhancement of chemosensitivity by 50%, 49% and 43%, 
respectively (Table 5), in comparison to the individual drugs 
and the siRNAs co-delivered without a drug. This suggests 
that both ABCG2 and ABCB1 are fully functional at a time 
in extruding any of those popular anti-cancer drugs from 
the cytoplasm of MCF-7 cells and inhibition or knockdown 
of a single transporter could only partly block the cellular 
efflux process, allowing drug efflux to continue through the 
other channel(s).
Table 5 Role of ABCg2 and ABCB1 knockdown in enhancing 
cytotoxic effects of anti-cancer drugs at 1 nM
siRNA % enhancement of chemosensitivity
Doxorubicin Paclitaxel Cisplatin
ABCG2 + ABCB1  
1 nM (each)
43% 49% 50%
ABCG2 1 nM 14% 17% 16%
ABCB1 1 nM 18% 26% 10%
Abbreviation: siRNA, small interfering RNA.
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Conclusion
Due to the heterogenous nature of tumours where several 
drug resistance mechanisms may coexist and simultaneously 
contribute to the development of cancer multidrug resistant-
phenotype,11 the use of siRNA combinations might represent 
a potential mechanism for circumventing this problem. 
  Additionally, the concern about saturating the cellular RNA 
interference machinery by exogenous addition of two siRNAs 
may have been potentially overcome by combining siRNAs 
at the lowest possible concentration. Thus, the synergism 
achieved with combination of ABCG2 and ABCB1 target-
ing siRNAs would provide valuable insight for complete 
reversal of clinical cancer multidrug resistance otherwise 
deemed impossible to be achieved by currently available 
therapeutics.
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